Status:

UNKNOWN

Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

Lead Sponsor:

China-Japan Friendship Hospital

Collaborating Sponsors:

The First Affiliated Hospital of Guangzhou Medical University

Beijing Chao Yang Hospital

Conditions:

Pulmonary Artery Sarcoma

Eligibility:

All Genders

Brief Summary

This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Detailed Description

This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Eligibility Criteria

Inclusion

  • Computed tomography pulmonary angiography indicated that there were intraluminal defects
  • Malignant histopathology was sarcoma
  • Informed consent form was signed

Exclusion

  • Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
  • Expected inability to complete follow-up

Key Trial Info

Start Date :

December 31 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2025

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06165718

Start Date

December 31 2022

End Date

June 30 2025

Last Update

December 15 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China, 100029

Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma. | DecenTrialz